10:30 AM EDT, 06/03/2025 (MT Newswires) -- Xeris Biopharma Holdings ( XERS ) shares fell 5.4% in recent Tuesday trading after the company reaffirmed 2025 revenue guidance of $260 million to $275 million.

Analysts polled by FactSet expect $268.1 million.

The company expects 2030 revenue of $750 million, led by Recorlev, a medicine for high cortisol levels in adults with Cushing's syndrome.

Xeris expects annual net revenue from Recorlev of $1 billion starting in 2035 and peak net revenue of $1 billion to $3 billion for XP-8121 to treat hypothyroidism with an injection under the skin.

Price: 4.78, Change: -0.29, Percent Change: -5.45